Acadia Healthcare Company, Inc. (NASDAQ:ACHC) Sees Significant Decrease in Short Interest

Acadia Healthcare Company, Inc. (NASDAQ:ACHC) was the target of a significant decline in short interest in July. As of July 31st, there was short interest totalling 22,575,038 shares, a decline of 6.5% from the July 14th total of 24,133,552 shares. Based on an average daily trading volume, of 1,039,897 shares, the days-to-cover ratio is currently 21.7 days. Currently, 27.6% of the shares of the stock are sold short.

Acadia Healthcare (NASDAQ ACHC) opened at 52.38 on Friday. The stock has a 50 day moving average price of $50.30 and a 200-day moving average price of $44.67. The stock has a market capitalization of $4.60 billion, a PE ratio of 575.60 and a beta of 1.15. Acadia Healthcare has a 12-month low of $32.54 and a 12-month high of $54.73.

Acadia Healthcare (NASDAQ:ACHC) last released its quarterly earnings results on Thursday, July 27th. The company reported $0.66 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.01. Acadia Healthcare had a net margin of 0.30% and a return on equity of 8.69%. The business had revenue of $715.90 million for the quarter, compared to analyst estimates of $717.38 million. During the same period in the previous year, the company earned $0.73 earnings per share. The business’s revenue for the quarter was down 5.4% on a year-over-year basis. On average, equities analysts anticipate that Acadia Healthcare will post $2.45 earnings per share for the current fiscal year.

Several equities analysts recently commented on the company. UBS AG restated a “positive” rating and set a $60.00 target price (up from $54.00) on shares of Acadia Healthcare in a research report on Monday, July 31st. Deutsche Bank AG boosted their target price on Acadia Healthcare from $58.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, July 31st. Craig Hallum restated a “buy” rating and set a $65.00 target price (up from $52.00) on shares of Acadia Healthcare in a research report on Monday, July 31st. BidaskClub cut Acadia Healthcare from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Finally, Zacks Investment Research cut Acadia Healthcare from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. Five research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Acadia Healthcare presently has a consensus rating of “Buy” and a consensus target price of $59.21.

In related news, Director Reeve B. Waud sold 50,000 shares of the business’s stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $45.09, for a total transaction of $2,254,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Scott Schwieger sold 2,891 shares of the business’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $52.85, for a total value of $152,789.35. Following the transaction, the insider now owns 8,841 shares of the company’s stock, valued at $467,246.85. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 2,136,347 shares of company stock valued at $105,383,249. 11.10% of the stock is owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Acadia Healthcare by 11.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,704 shares of the company’s stock valued at $134,000 after buying an additional 270 shares in the last quarter. Riverhead Capital Management LLC purchased a new position in Acadia Healthcare during the second quarter valued at about $209,000. Emerald Mutual Fund Advisers Trust purchased a new position in Acadia Healthcare during the first quarter valued at about $210,000. World Asset Management Inc purchased a new position in Acadia Healthcare during the second quarter valued at about $242,000. Finally, Paloma Partners Management Co purchased a new position in Acadia Healthcare during the first quarter valued at about $217,000.

TRADEMARK VIOLATION NOTICE: “Acadia Healthcare Company, Inc. (NASDAQ:ACHC) Sees Significant Decrease in Short Interest” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.com-unik.info/2017/08/12/acadia-healthcare-company-inc-nasdaqachc-sees-significant-decrease-in-short-interest.html.

Acadia Healthcare Company Profile

Acadia Healthcare Company, Inc is a provider of behavioral healthcare services, with operations in the United States and the United Kingdom. The Company focuses on acquiring and developing behavioral healthcare facilities. The Company operates through two segments: U.S. Facilities and U.K. Facilities.

What are top analysts saying about Acadia Healthcare Company Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Acadia Healthcare Company Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit